UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
Key Details
- 12025 San Antonio Breast Cancer Symposium features UCLA-led research in early detection, precision medicine, and artificial intelligence.
- 2A study of 2,200+ breast cancer cases showed an AI tool (Ataraxis Breast) surpassed current criteria in identifying high-risk HR+/HER2– patients for CDK4/6 therapy.
- 3Research using liquid biopsy (ctDNA) found negative results were linked to less anxiety and greater well-being in survivors.
- 4Simple immune blood markers before treatment predicted pathologic response to neoadjuvant immunotherapy in triple-negative breast cancer.
- 5AI-driven pathology may refine treatment selection, and liquid biopsies show promise in both outcomes tracking and patient support.
Why It Matters
These advances suggest AI and blood-based diagnostics may dramatically improve risk stratification, treatment selection, and quality of life in breast cancer care. The findings point to imminent shifts in clinical workflows and highlight the growing role of artificial intelligence in precision oncology.
Source
EurekAlert
Related News
•EurekAlert
NIH Invests Additional $12.6M in USC-Led Imaging AI for Alzheimer's
NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.